References
- Balgobin S, Maldonado PA, Chin K, Schaffer JI, Hamid CA. 2016. Safety of manual morcellation after vaginal or laparoscopic-assisted vaginal hysterectomy. Journal of Minimally Invasive Gynecology 23:542–547.
- Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. 2008. The utility of preoperative endometrial sampling for the detection of uterine sarcomas. Gynecologic Oncology 110:43–48.
- Bojahr B, De Wilde RL, Tchartchian G. 2015. Malignancy rate of 10,731 uteri morcellated during laparoscopic supracervical hysterectomy (LASH). Archives of Gynecology and Obstetrics 292:665–672.
- Coffey D, Kaplan AL, Ramzy I. 2005. Intraoperative consultation in gynecologic pathology. Archives of Pathology & Laboratory Medicine 129:1544–1557.
- Cui RR, Wright JD. 2016. Risk of occult uterine sarcoma in presumed uterine fibroids. Clinical Obstetrics and Gynecology 59:103–118.
- D’angelo E, Prat J. 2010. Uterine sarcomas: a review. Gynecologic Oncology 116:131–139.
- Food & Administration, D., 2014. Quantitative assessment of the prevalence of unsuspected uterine sarcoma in women undergoing treatment of uterine fibroids. Summary and key findings. http://www.fda.gov/downloads/MedicalDevices/Safety/AlertsandNotices/UCM393589.pdf.
- Food U, Administration D. 2018. FDA updated assessment of the use of laparoscopic power morcellators to treat uterine fibroids. Silver Spring (MD): FDA; 2017. FDA Safety Communication.
- Hanley KZ, Birdsong GG, Mosunjac MB. 2017. Recent developments in surgical pathology of the uterine corpus. Archives of Pathology & Laboratory Medicine 141:528–541.
- Liu FW, Galvan-Turner VB, Pfaendler KS, Longoria TC, Bristow RE. 2015. A critical assessment of morcellation and its impact on gynecologic surgery and the limitations of the existing literature. American Journal of Obstetrics and Gynecology 212:717–724.
- Pritts EA, Vanness DJ, Berek JS, Parker W, Feinberg R, Feinberg J, Olive DL. 2015. The prevalence of occult leiomyosarcoma at surgery for presumed uterine fibroids: a meta-analysis. Gynecological Surgery 12:165–177.
- Raspagliesi F, Maltese G, Bogani G, Fucà G, Lepori S, De Iaco P, et al. 2017. Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: a retrospective MITO group study. Gynecologic Oncology 144:90–95.
- Thomassin-Naggara I, Dechoux S, Bonneau C, Morel A, Rouzier R, Carette M-F, et al. 2013. How to differentiate benign from malignant myometrial tumours using MR imaging. European Radiology 23:2306–2314.
- Wang L, Li S, Zhang Z, Jia J, Shan B. 2020. Prevalence and occult rates of uterine leiomyosarcoma. Medicine 99:e21766.
- Wu CQ, Woo LY, Giede KC, Thiel J, Karreman E, Rattray DD. 2019. Occult leiomyosarcomas in a Canadian province: a retrospective cohort study. Journal of Obstetrics and Gynaecology Canada 41:46–51.
- Yorgancı A, Meydanlı MM, Kadıoğlu N, Taşkın S, Kayıkçıoğlu F, Altın D, et al. 2020. Incidence and outcome of occult uterine sarcoma: a multi-centre study of 18604 operations performed for presumed uterine leiomyoma. Journal of Gynecology Obstetrics and Human Reproduction 49:101631.